GERRESHEIMER should benefit from the launch of Wegovy in Japan. GLP1 products offer a sales opportunity of several hundred million euros!

• Novo Nordisk launches Wegovy in Japan on 02-22-2024. GLP-1 products will boom in the next few years!
• Gerresheimer supplies all relevant GLP-1 manufacturers with drug delivery systems. The share now has recovery potential!

Novo Nordisk announced today that it plans to launch the weight loss drug Wegovy in Japan on February 22, 2024. This would be the sixth country where the anti-obesity product would be available, despite bottlenecks due to high demand. Gerresheimer is a beneficiary of internationalization, as the Group has all major GLP-1 manufacturers as customers for syringes, pens and autoinjectors.

Gerresheimer believes it is well positioned to secure a significant share of primary packaging and drug delivery systems. The relevant market is worth $1.2-2.4 billion with a market volume of $60 billion for GLP-1 products. Accordingly, Gerresheimer sees the opportunity for sales of several hundred million euros.

The share has undergone a correction in recent weeks. The fall in the share price has made the stock attractive again. The growing internationalization of GLP-1 products is positive for Gerresheimer and should support the share.

Want to keep reading?

You can find the entire story in The Trader Times. Get a 4-week trial subscription now and access the entire archive!